Body dysmorphic disorder
disease diseaseOn this page
Also known as dysmorphophobia
Summary
Body dysmorphic disorder (MONDO:0000690) is a disease and 46 clinical trials. Top therapeutic interventions include dextromethorphan, fluoxetine, and venlafaxine. A subtype of somatoform disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 46
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | body dysmorphic disorder |
| Mondo ID | MONDO:0000690 |
| MeSH | D057215 |
| DOID | DOID:0060163 |
| ICD-10-CM | F45.22 |
| ICD-11 | 731724655 |
| SNOMED CT | 83482000 |
| UMLS | C0005887 |
| MedGen | 2302 |
| Is cancer (heuristic) | no |
Also known as: dysmorphophobia
Disease family
This is a subtype of somatoform disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › somatoform disorder › body dysmorphic disorder
Related subtypes (5): neurocirculatory asthenia, hypochondriasis, somatization disorder, conversion disorder, physiological malfunction arising from mental factor
Subtypes (1): muscle dysmorphic disorder
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 46.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 37 |
| PHASE2 | 5 |
| PHASE4 | 3 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00211809 | PHASE4 | TERMINATED | CBT as an Adjunct to SRIs in the Treatment of BDD |
| NCT00245635 | PHASE4 | COMPLETED | Fluoxetine in Pediatric Body Dysmorphic Disorder |
| NCT00265109 | PHASE4 | COMPLETED | Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder |
| NCT04899687 | PHASE2 | RECRUITING | Study of Dextromethorphan in OCD and Related Disorders |
| NCT01316627 | PHASE2 | UNKNOWN | Study of Patients With Body Image Issues Treated With 2 Different Behavioral Interventions |
| NCT02671266 | PHASE2 | COMPLETED | Oxytocin Administration in BDD and OCD |
| NCT02843451 | PHASE2 | WITHDRAWN | Milk Thistle in Body Dysmorphic Disorder |
| NCT04656301 | PHASE2 | COMPLETED | Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder |
| NCT00842309 | EARLY_PHASE1 | COMPLETED | D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder |
| NCT01075672 | Not specified | ACTIVE_NOT_RECRUITING | Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals |
| NCT03918577 | Not specified | RECRUITING | Caloric Vestibular Stimulation for Modulation of Insight in Obsessive-Compulsive Spectrum Disorders |
| NCT04373629 | Not specified | RECRUITING | Perceptual Abnormalities and Their Malleability in BDD |
| NCT04804800 | Not specified | NOT_YET_RECRUITING | Virtual Reality Place in the Management of Body Dysmorphia Disorders in Anorexia Nervosa |
| NCT06262412 | Not specified | RECRUITING | Internet-delivered Cognitive-behaviour Therapy for Child and Adolescent Body Dysmorphic Disorder |
| NCT06346301 | Not specified | RECRUITING | Imagery Rescripting as a Stand-alone Treatment for OCD and BDD. |
| NCT06678295 | Not specified | RECRUITING | Individual Factors of CBT Underlying Success |
| NCT06781853 | Not specified | ACTIVE_NOT_RECRUITING | CBT for Muscle Dysmorphia and Steroid Abuse: A Randomized Controlled Trial |
| NCT07036744 | Not specified | RECRUITING | When The Mirror Is Wrong |
| NCT07589621 | Not specified | NOT_YET_RECRUITING | Safety Behavior Fading Versus Progressive Muscle Relaxation for Appearance Concerns |
| NCT00106223 | Not specified | COMPLETED | Treatment Study Investigating New Cognitive Behavioral Therapy Treatment Manual for Body Dysmorphic Disorder |
| NCT00871143 | Not specified | COMPLETED | Cognitive Behaviour Therapy (CBT) for Body Dysmorphic Disorder (BDD) |
| NCT01002326 | Not specified | COMPLETED | Cognitive-Behavioral Therapy for Pediatric Body Dysmorphic Disorder |
| NCT01038128 | Not specified | COMPLETED | An Open Label Trial of Memantine in the Treatment of Bulimia Nervosa and Body Dysmorphic Disorder |
| NCT01093950 | Not specified | UNKNOWN | White Light Scanning to Aid Body Contouring: A Pilot Project |
| NCT01398865 | Not specified | COMPLETED | Escitalopram Neuroimaging Supplement |
| NCT01398904 | Not specified | COMPLETED | Attentional Bias in Body Dysmorphic Disorder |
| NCT01453439 | Not specified | COMPLETED | Cognitive-Behavioral Therapy and Supportive Psychotherapy for Body Dysmorphic Disorder |
| NCT02010619 | Not specified | COMPLETED | Internet Delivered CBT for Body Dysmorphic Disorder |
| NCT02524301 | Not specified | COMPLETED | Evaluation of Brain Opioid Receptor Activity in Anorexia Nervosa : a PET [11C]Diprenorphine Study |
| NCT02635152 | Not specified | COMPLETED | Interpretation Bias Modification for Body Dysmorphic Disorder |
| NCT02808702 | Not specified | COMPLETED | Brain Correlates of Self-Focused Processing |
| NCT03221738 | Not specified | COMPLETED | Smartphone-Administered App Treatment for Adults With Body Dysmorphic Disorder |
| NCT03517384 | Not specified | COMPLETED | Feasibility Pilot Study of Internet-based Cognitive Behavioral Therapy (CBT) for Body Dysmorphic Disorder With Global Recruitment |
| NCT03673046 | Not specified | COMPLETED | Waitlist-Control Trial of Smartphone Cognitive Behavioral Therapy (CBT) for Body Dysmorphic Disorder (BDD) |
| NCT03773549 | Not specified | COMPLETED | A Virtual Reality Study of Cognitive Biases in Body Dysmorphic Disorder |
| NCT04103606 | Not specified | COMPLETED | A Mobile-App Training to Reduce Body Image Disorder Symptoms and Associated Features in Female University Students |
| NCT04254575 | Not specified | COMPLETED | Understanding Daily Changes in BDD Risk Using Smartphones |
| NCT05078320 | Not specified | COMPLETED | Internet-delivered Cognitive-behaviour Therapy for Adolescents With Body Dysmorphic Disorder |
| NCT05402475 | Not specified | UNKNOWN | Online Cognitive Behavioural Therapy Intervention for Body Dysmorphic Disorder |
| NCT05607121 | Not specified | COMPLETED | TMS Visual Modulation in Body Dysmorphic Disorder |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DEXTROMETHORPHAN | 4 | 3 |
| FLUOXETINE | 4 | 3 |
| VENLAFAXINE | 4 | 3 |
| CYCLOSERINE | 4 | 1 |
| LEVETIRACETAM | 4 | 1 |
| MILK THISTLE | 3 | 1 |
| PSILOCYBIN | 3 | 1 |
| ETIRACETAM | 2 | 1 |
| LEVCYCLOSERINE | 2 | 1 |
| MEBUFOTENIN | 2 | 1 |
| LEVITIRACETAM | 0 | 1 |